Human tobacco-related cancers exhibit a high frequency of G to T transversions in the mutation hot spot region of the p53 tumor suppressor gene, possibly the result of specific mutagens in tobacco smoke, most notably benzo [a] An increasing body of molecular epidemiological evidence suggests that regions ofthe p53 gene may be a selective target of environmental carcinogens etiologically associated with specific human cancers (4-19). In this context, a high frequency of G to T transversions in the mutation hot spot regions of the p53 gene (2, 3) have been identified in human hepatocellular carcinomas and strongly correlated with the mutagenic effects of dietary aflatoxin B1 exposurf (4, (13) (14) (15) .
wide variety of human tumors (see refs. 2 and 3) and appear to be one of the most frequent genetic alterations in human neoplasias (1, 2) .
An increasing body of molecular epidemiological evidence suggests that regions ofthe p53 gene may be a selective target of environmental carcinogens etiologically associated with specific human cancers (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . In this context, a high frequency of G to T transversions in the mutation hot spot regions of the p53 gene (2, 3) have been identified in human hepatocellular carcinomas and strongly correlated with the mutagenic effects of dietary aflatoxin B1 exposurf (4, [13] [14] [15] .
Similarly, UV-B-specific dipyrimidine G to T transitions in the p53 gene have been characterized in human squamous cell carcinomas of the skin (16, 17) . Unique mutations in p53 have likewise been reported in radon-associated lung cancers (18) and in human epithelial cells exposed to nickel(II) in vitro (19) , providing evidence for an important molecular target for the genotoxic effects of these agents. Of particular clinical and epidemiological interest are the observations of a high frequency of G to T transversions among p53 mutations in tobacco-related human neoplasias, including small-cell and non-small-cell lung cancers (5) (6) (7) (8) , esophageal carcinomas (10) (11) (12) , and squamous cell carcinomas of the head and neck (9) . In several ofthese studies, the presence of p53 mutations in tumors was strongly correlated with lifetime cigarette consumption (7) or a history of heavy smoking (9) .
It has been suggested (4) (5) (6) (7) (8) (9) (10) (11) (12) that the frequent G to T transversion in the p53 gene in tobacco-related cancers may be associated with specific mutagens in tobacco smoke, most notably activated benzo[a]pyrene (B[a]P) species (4, 20, 21 (23) . Tumors and lung metastases were characterized histopathologically as described (24) following hematoxylin/eosin staining. Primary explant cultures of skin tumors were prepared as described (22) . Papillomas harvested for analyses were subjected to 35-38 weeks of B[a]P treatment, while carcinomas analyzed were subjected to 50 weeks of carcinogen exposure. In the complete carcinogenesis protocol with DMBA, papillomas and carcinomas used in molecular analyses were obtained from mice subjected to 34-52 weeks of carcinogen exposure. The two-stage carcinogenesis protocol using DMBA as initiator has been described (22 frozen sections of each specimen were fixed in acetone for 15 min at 4°C. Analysis of the p53 protein was done with hybridoma supernatants of monoclonal antibodies pAb421 (25) and pAb248 (26) at a dilution of 1:20 by a conventional avidin-biotin immunoperoxidase technique (Vectastain; Vector Laboratories) and with diaminobenzidine (1 mg/ml in 0.02% hydrogen peroxide) used as a chromogenic agent as detailed (27) .
PCR Amplifilcation and Sequence Analysis of the Murine p53 Gene. Genomic DNA was obtained from a total of 8 papillomas and 12 squamous cell carcinomas induced by B[a]P, and 3 papillomas and 33 carcinomas induced by DMBA, 8 of which were reported elsewhere (22), as described (28) . Samples were subjected to 35 cycles of PCR amplification using murine-specific intronic primers for exons 5-8 inclusive of the p53 gene as described (29) . All PCR amplification primers were contained within intron sequences to avoid amplification of the murine p53 pseudogene (29) . Each amplification cycle consisted of 94°C (1.17 min), 62°C (1 min), and 72°C
(1.25 min) after an initial denaturation step (94°C for 5 min). After purification of PCR products by Sephadex G-25 filtration, direct sequence analysis of each exon 5-8 of murine p53 was done using T4 [y-32P]polynucleotide kinase-end-labeled sequencing primers as described by Goodrow et aL (29) . Tumor genomic DNA/PCR products were resequenced using corresponding sense or antisense sequencing primers for each exon and/or a separate PCR product to verify specific mutations (22, 29) .
RESULTS
The complete carcinogenesis protocol with B[a]P and DMBA resulted in production of both papillomas and carcinomas, with the latter varying in histopathological grade from welldifferentiated squamous carcinomas (grade I) to anaplastic, spindle-type tumors (grade IV). Moreover, many of the Table 1 observed papillomas were marked by cellular atypia and dysplasia.
Immunohistochemical analyses of the p53 protein in frozen sections of 13 papillomas and 13 carcinomas induced by B[a]P with antibodies pAb421 and pAb248 revealed the absence of nuclear reactivity for p53 in all papillomas but positive nuclear staining in 62% of the carcinomas (Table 1 and Fig. 1 A and B) . Carcinomas exhibiting positive nuclear reactivity for p53 ranged from stages I to IV in histopathological grade. As depicted in Fig. 1 A and B, frozen sections of immunohistochemically positive and negative tumors with pAb248 reveal some background epithelial staining, especially in the superficial layers, while primary explant cultures did not exhibit this pattern (Fig. 1C) .
To confirm and characterize suspect p53 mutations in the B[a]P-induced tumors, direct sequence analysis of exons 5-8
inclusive of the murine p53 gene was undertaken in PCRamplified genomic DNA from 8 papillomas, and 12 primary B[a]P carcinomas, 5 of which were immunohistochemically positive for nuclear p53 reactivity, 4 of which demonstrated no nuclear p53 staining, and 3 of which were selected randomly without immunohistochemical verification. As shown in Table 2 and ative carcinomas, predominantly in exons 7 and 8 of the p53 gene, giving rise to a mutation frequency of 33% in Bla]Pinduced tumors. Two of the identified G to T transversions resulted in silent mutations at the amino acid level ( Table 2 ). The data suggest that the absence of nuclear p53 immunoreactivity is not an absolute criteria for the presence of a wild-type p53 gene in this tumor model.
Most notably of the seven missense mutations in Bla]Pinduced tumors, all confirmed on a second PCR product and/or by resequencing a given exon with a corresponding antisense primer, all mutations targeted guanine residues and 71% (5/7) were G to T transversions; the remaining two were G to A and G to C alterations. This pattern of G to T transversions is the predominant mutation induced by activated-B[a]P diol epoxides in in vitro studies (4, 20, 21) gens, sequence analyses were undertaken on 3 papillomas and 17 squamous cell carcinomas induced by a complete carcinogenesis protocol with DMBA. As shown in Table 2 , a total of six heterozygous mutations were confirmed in DMBA-induced tumors, yielding a frequency similar to that observed in B[a]P-induced tumors. Moreover, the majority of mutations (5/6) were identified in squamous cell carcinomas; only a single atypical and dysplastic papilloma revealed a p53 mutation. Ofthe mutations identified in tumors induced by complete carcinogenesis with DMBA, three were missense mutations, two were phenotypically silent, and one was a nonsense mutation. Most notably, only a single G to T transversion was identified among these 20 tumors. Moreover, in a previous study of p53 alterations in DMBA/PMAinduced mouse skin tumors, 2 of 8 carcinomas revealed p53 mutations, none of which were G to T transversions (22) . Sequence analyses of an additional 8 DMBA/PMA-induced skin tumors revealed a G to A transition in codon 270 and-an A to G transition in codon 219 (Table 2) 
DISCUSSION
The results of the present study of p53 mutations in murine B[a]P-induced skin tumors reveal a 33% frequency of missense mutations predominantly G to T transversions in exons 7 and 8 of the p53 gene and a 62% frequency of immunohistochemically positive carcinomas. In contrast, papillomas induced by this protocol were immunohistochemically negative for p53 nuclear staining, and only a single p53 mutation was found by DNA sequence analysis. Mutations were not Medical Sciences: Ruggeri et al.
identified in every immunohistochemically positive tumor by sequence analysis. The possibility that p53 mutations in these tumors reside outside of the highly conserved regions of the p53 gene or in promoter and enhancer regions of the gene, resulting in overexpression of the p53 protein, has been addressed by others (30) . These in vivo findings lend support to in vitro analyses (4) and molecular epidemiological studies of human tobacco-related cancers (4) (5) (6) (7) (8) (9) (10) (11) (12) , suggesting that activated B[a]P species may form adducts with predominantly guanine residues of the p53 gene and induce a high frequency of G to T transversions. Comparative analyses of the p53 mutation spectra in DMBA-induced skin tumors strengthens this supposition; while the frequency of mutations is similar, G to T transversions are rare in DMBAinduced and DMBA/PMA-induced (Table 2 ) skin tumor models of squamous cell neoplasias. This is supported by the fact that no tumor cell line derived from DMBA-induced tumors contains G to T transversions (22 (24, 35) although carcinomas may also arise directly from nonpapillomatous skin exposed to carcinogen (24) .
Previous studies in our laboratory (22) and others (31) 
